Dr. Tzachanis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Drive
MC 0960
La Jolla, CA 92093Phone+1 858-822-6600Fax+1 858-822-6844- Is this information wrong?
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2000 - 2003
- Aristotle University of Thessaloniki School of MedicineClass of 1997
Certifications & Licensure
- CA State Medical License 2012 - 2024
- MA State Medical License 2003 - 2018
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Start of enrollment: 2019 Nov 26
Publications & Presentations
PubMed
- Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Ke...> ;Bone Marrow Transplantation. 2024 Mar 1
- Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience.Aaron Trando, Anna Ter-Zakarian, Phillip Yeung, Aaron M Goodman, Ayad Hamdan, Michael Hurley, Ah-Reum Jeong, Dimitrios Tzachanis> ;Cancers. 2023 Sep 21
- 2 citationsImpact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with bre...Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzac...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
- Join now to see all
Abstracts/Posters
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell TherapyJune 3rd, 2021
- Dr. Tzachanis on Data with Lisocabtagene Maraleucel in LymphomaFebruary 28th, 2020
- Cancer Cell Therapy Success Grows, but Hospitals Struggle with CostOctober 4th, 2019
Professional Memberships
- Member
Hospital Affiliations
- UC San Diego Medical Center - HillcrestSan Diego, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: